key: cord-0971196-hjwccpst authors: Alghizzawi, Mohd Islam; Ata, Fateen; Yousaf, Zohaib; Alhiyari, Mousa Ahmad; Bint I Bilal, Ammara; Elhiday, Abdelhaleem Ahmed; Abdulhadi, Ahmad Salih title: The second wave of desaturation in COVID-19 date: 2021-03-19 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2021.100866 sha: b594baef037613d78f70edf0e8ac2a378c2f89f9 doc_id: 971196 cord_uid: hjwccpst After a complete symptomatic recovery after COVID-19 pneumonia, the second phase of desaturation is a new phenomenon that is being increasingly observed. Two possible mechanisms behind it can be a continued subclinical infection and lung fibrosis. We have presented a case with the former mechanism, who responded well to steroids. After a complete symptomatic recovery after COVID-19 pneumonia, the second phase of desaturation is a 2 new phenomenon that is being increasingly observed. Two possible mechanisms behind it can be a 3 continued subclinical infection and lung fibrosis. We have presented a case with the former mechanism, 4 who responded well to steroids. In late 2019, a novel corona virus, severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), was 27 identified in the human body and led to a pandemic [1] . Understanding the spectrum of this disease, it's 28 prevention and optimal clinical management is the current focus of physicians and researchers around the 29 globe. Many drugs have been and are being investigated for their role in the management of COVID-19 30 infection. Remdesevir has shown potential in decreasing hospital stay among COVID-19 infected patients 31 [2]. Dexamethasone has shown a mortality benefit in severe . However, the current 32 management of SARS-CoV-2 pneumonia and ARDS focuses mainly on providing supportive measures 33 The clinical course in COVID-19 varies from asymptomatic disease to fulminant ARDS [5] . There is 35 anecdotal evidence about persisting dyspnea following treatment of COVID-19. Post-COVID pulmonary 36 fibrosis is hypothesized to be one of the etiologies behind this phenomenon [6] .Also, post-treatment; an 37 asymptomatic patient may develop a subclinical infectious process. This subclinical infection may lead to 38 a second phase of desaturation. There are currently no guidelines on the treatment of this second phase of 39 desaturation. We present a case monitored the response of steroids in our patient who had desaturation 40 secondary to an ongoing residual subclinical inflammation after he was treated for COVID-19 41 pneumonia. Our patient had an excellent response to steroids; hence we postulate that steroids can be a 42 potential treatment for such patients. presented to the hospital with one day history of dyspnea. He was treated for COVID-19 pneumonia and 47 was discharged one day prior to his readmission. His initial presentation was with dyspnea, fever, fatigue, consolidations with air bronchograms [ Figure 2 ]. 64 He was tested again for COIVD-19, but the RT-PCR result came negative, ruling out a possibility of 65 reinfection. The sepsis workup did not reveal any bacterial growth (including Mycoplasma pneumonia, 66 Legionella pneumophila and Chlamydia pneumonia). Nasopharyngeal PCR for common respiratory 67 viruses (including Influenza, Parainfluenza, Respiratory syncytial virus and Middle East respiratory 68 syndrome coronavirus) were negative. A bronchoscopy performed to rule out tuberculosis (TB), 69 eosinophilic pneumonia or pulmonary hemorrhage was unrevealing. 70 As the patient continued to have desaturation, a multidisciplinary team decided to start a trail of 60 mg 71 prednisolone for 2 weeks. He responded very well, and oxygen requirement decreased. He was off 72 oxygen at rest in two days and was discharged with a follow-up in pulmonary clinic. 73 Repeated CXR after 2 weeks from discharge showed significant regression on bilateral infiltrate [ Figure 74 1c]. Pulmonary Function Test (PFT) was done, which showed a restrictive pattern with decreased 75 Diffusing capacity for carbon monoxide (DLCO) [ Figure 3 ]. A 6 minute walking test showed a vivid 76 improvement compared to his previous condition where was not able to complete more than 3 minutes of 77 walking. mild to moderate, whereas around 20 % progress to severe and critical illness. The long-term Respiratory hydroxychloroquine, Interleukin-6 pathway inhibitors such as tocilizumab, convalescent plasma, 88 remdesivir and dexamethasone [2, 3, [9] [10] [11] ]. Among all the tested treatment modalities, the most 89 promising results are from remdesivir and dexamethasone, as the preliminary reports show a reduction in 90 hospital stay from the former and a reduced mortality by the latter. 91 The RECOVERY trial is investigating the role of dexamethasone in SARS-CoV-2 infection. Initial 92 results show a decreased 28-day mortality in the treatment arm. However, this effect is seen only in the 93 subset of patients requiring invasive and non-invasive mechanical ventilation [3] . Consequently, current 94 guidelines recommend the use of dexamethasone only in moderate to severely ill patients [12] . 95 In some patients, a second phase of dyspnea is seen after an interval asymptomatic recovery phase in 96 patients successfully treated for COVID-19 pneumonia or ARDS. We propose two possible mechanisms 97 behind this, post-infection fibrotic changes in the lungs or a continued subclinical infective process which 98 becomes symptomatic again after some time. Fibrotic lung changes are reported in survivors with 99 COVID-19 pneumonia and abnormalities in lung function have been detected in COVID-19 patients 100 shortly after the discharge from the hospital [6, 13] . Our patient suffered from ongoing lung damage 101 despite viral clearance and symptomatic recovery. This resulted in chronic lung changes as the pulmonary 102 function test revealed a restrictive pattern with decreased diffusion capacity. 103 Pulmonary fibrosis usually occurs secondary to dysregulated healing process. Chronic inflammation can 104 lead to fibrosis. The changes in the cellular and molecular environment in the lung tissue secondary to 105 viral infection as in COVID are the key factors behind the fibrosis [14] . 106 The ongoing damage takes place in the tissues secondary to the inflammation leading to an over 107 expression of inflammatory cytokines, including transforming growth factor-1, tumor necrosis factor-a 108 (TNF-a), interleukin-1, and interleukin-6 (IL-6). This in turn stimulates the proliferation of type 2 alveolar 109 cell and increase in fibroblast recruitment [15, 16] . Eventually, the cascade can lead to an increase the 110 production and deposition of extracellular matrix (ECM), impairing gas exchange and hence leading to 111 hypoxemia [16] . 112 The long-term reversible and irreversible respiratory sequelae of COVID-19-remain obscure, as does the 113 patient population at a high risk to develop them. Our patient had an excellent recovery with steroids. 114 Authors are of the view that a large scale randomized controlled trial is required to establish the efficacy 115 of steroids in post-COVID-19 recurrent dyspnea. Treatment options for COVID-19: The reality and challenges Remdesivir for the 173 Treatment of Covid-19 -Preliminary Report Dexamethasone in 175 Hospitalized Patients with Covid-19 -Preliminary Report Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev 177 Drug Discov Clinical course and mortality risk of severe COVID-19 19 Pneumonia 181 Pulmonary Fibrosis. QJM Clinical features of patients infected with 183 2019 novel coronavirus in Wuhan COVID-19: 188 consider cytokine storm syndromes and immunosuppression Convalescent plasma or 191 hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane 192 Database Syst Rev Hydroxychloroquine in patients with 194 mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial A living WHO 197 guideline on drugs for covid-19 Abnormal pulmonary function in COVID-199 19 patients at time of hospital discharge Pulmonary fibrosis: pathogenesis, etiology and regulation Fibroblasts in fibrosis: novel roles and mediators. Front 203 Pharmacol Pulmonary fibrosis: cellular and molecular events The second wave of desaturation after resolution of symptoms post-COVID-19 treatment is a rare 118 phenomenon. It can be secondary to an ongoing subclinical infection or due to fibrosis. The role of 119 steroids is not studied in this scenario. Our patient had a dramatic response to steroids indicating a Availability of data and materials:Competing interests: